- Volume 16 Issue 12
DOI QR Code
Vietnamese Health Care Providers' Preferences Regarding Recommendation of HPV Vaccines
- Asiedu, Gladys B (Department of Health Sciences Research, Division of Health Care Policy and Research, Mayo Clinic) ;
- Breitkopf, Carmen Radecki (Department of Health Sciences Research, Division of Health Care Policy and Research, Mayo Clinic) ;
- Kremers, Walter K (Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, Mayo Clinic) ;
- Ngo, Quang V (Da Nang Center for Reproductive Health) ;
- Nguyen, Nguyen V (Department of Radiology, Jackson Memorial Hospital/University of Miami) ;
- Barenberg, Benjamin J (Female Pelvic Medicine and Reconstructive Surgery, Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center) ;
- Tran, Vinh D (Da Nang Hospital for Women and Children) ;
- Dinh, Tri A (Department of Gynecologic Oncology & Gynecologic Surgery, Mayo Clinic)
- 발행 : 2015.07.13
Physician recommendation is an important predictor of HPV vaccine acceptance; however, physician willingness and preferences regarding HPV vaccination may be influenced by factors including patient age, vaccine type, and cost. A cross-sectional survey was administered to a convenience sample of health care providers in Da Nang, Vietnam, to evaluate awareness, perceptions about HPV and HPV vaccines, and willingness to vaccinate a female patient. Willingness to vaccinate was evaluated using a full-factorial presentation of scenarios featuring the following factors: vaccine cost (free vs 1,000,000 VND), patient age (12, 16, or 22 years), and HPV vaccine type (bivalent vs quadrivalent). Responses from 244 providers were analyzed; providers had a mean age of
- Breitkopf CR, Pearson HC, Dinh TA, et al (2009). Human papillomavirus vaccine decision-making in Da Nang, Vietnam: perceived spousal and adolescent-parent concordance. Vaccine, 27, 2367-71. https://doi.org/10.1016/j.vaccine.2009.02.021
- Bruni L, Barrionuevo-Rosas L, Albero G, et al (2014). ICO information centre on HPV and cancer (HPV information centre). human papillomavirus and related diseases in Viet Nam. Summary Report 2014-12-18. http://www.hpvcentre.net/statistics/reports/VNM.pdf.
- Caskey R, Lindau ST, Alexander GC (2009). Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. J Adolesc Health, 45, 453-62. https://doi.org/10.1016/j.jadohealth.2009.04.021
- Centers for Disease Control and Prevention (2013a). HPV vaccine information for clinicians - fact sheet. http://www.cdc.gov/std/hpv/stdfact-hpv-vaccine-hcp.htm.
- Centers for Disease Control and Prevention (2013b). HPV Vaccines. http://www.cdc.gov/hpv/vaccine.html.
- Centers for Disease Control and Prevention (2013c). National and state vaccination coverage among adolescents aged 13-17 years--United States, 2012. MMWR Morb Mortal Wkly Rep, 62, 685-93.
- Cover JK, Nghi NQ, LaMontagne DS, et al (2012). Acceptance patterns and decision-making for human papillomavirus vaccination among parents in Vietnam: an in-depth qualitative study post-vaccination. BMC Public Health, 12, 629. https://doi.org/10.1186/1471-2458-12-629
- Daley MF, Liddon N, Crane LA, et al (2006). A national survey of pediatrician knowledge and attitudes regarding human papillomavirus vaccination. Pediatrics, 118, 2280-9. https://doi.org/10.1542/peds.2006-1946
- Dinh TA, Rosenthal SL, Doan ED, et al (2007). Attitudes of mothers in Da Nang, Vietnam toward a human papillomavirus vaccine. J Adolesc Health, 40, 559-63. https://doi.org/10.1016/j.jadohealth.2007.02.003
- Do H, Seng P, Talbot J, et al (2009). HPV vaccine knowledge and beliefs among Cambodian American parents and community leaders. Asian Pac J Cancer Prev, 10, 339-44.
- Dunne EF, Unger ER, Sternberg M, et al (2007). Prevalence of HPV infection among females in the United States. JAMA, 297, 813-9. https://doi.org/10.1001/jama.297.8.813
- Gargano LM, Herbert NL, Painter JE, et al (2013). Impact of a physician recommendation and parental immunization attitudes on receipt or intention to receive adolescent vaccines. Hum Vaccin Immunother, 9, 2627-33. https://doi.org/10.4161/hv.25823
- Harper DM, Franco EL, Wheeler C, et al (2004). Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet, 364, 1757-65. https://doi.org/10.1016/S0140-6736(04)17398-4
- Harper DM, Franco EL, Wheeler CM, et al (2006). Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet, 367, 1247-55. https://doi.org/10.1016/S0140-6736(06)68439-0
- Hoang HT, Ishizaki A, Nguyen CH, et al (2013). Infection with high-risk HPV types among female sex workers in northern Vietnam. J Med Virol, 85, 288-94. https://doi.org/10.1002/jmv.23456
- Hofstetter AM, Stockwell MS, Al-Husayni N, et al (2014). HPV vaccination: are we initiating too late? Vaccine, 32, 1939-45. https://doi.org/10.1016/j.vaccine.2014.01.084
- International Agency for Research on Cancer (IARC). GLOBOCAN 2012: Cervical cancer estimated incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/pages/fact_sheets_cancer.aspx.
- Kahn JA, Rosenthal SL, Tissot AM, et al (2007). Factors influencing pediatricians' intention to recommend human papillomavirus vaccines. Ambul Pediatr, 7, 367-73. https://doi.org/10.1016/j.ambp.2007.05.010
- Kester LM, Zimet GD, Fortenberry JD, et al (2013). A national study of HPV vaccination of adolescent girls: rates, predictors, and reasons for non-vaccination. Matern Child Health J, 17, 879-85. https://doi.org/10.1007/s10995-012-1066-z
- Kim JJ, Kobus KE, Diaz M, et al (2008). Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. Vaccine, 26, 4015-24. https://doi.org/10.1016/j.vaccine.2008.05.038
- LaMontagne DS, Barge S, Le NT, et al (2011). Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ, 89, 821-30. https://doi.org/10.2471/BLT.11.089862
- Lamontagne DS, Thiem VD, Huong VM, et al (2013). Immunogenicity of quadrivalent HPV vaccine among girls 11 to 13 Years of age vaccinated using alternative dosing schedules: results 29 to 32 months after third dose. J Infect Dis, 208, 1325-34. https://doi.org/10.1093/infdis/jit363
- Long LD, Population Council (Vietnam), United Nations Population Fund (2000). The Doi Moi generation: coming of age in Vietnam today. Hanoi, Vietnam: Population Council.
- Miyashita M, Agdamag DM, Sasagawa T, et al (2009). High-risk HPV types in lesions of the uterine cervix of female commercial sex workers in the Philippines. J Med Virol, 81, 545-51. https://doi.org/10.1002/jmv.21416
- Molano M, Van den Brule A, Plummer M, et al (2003). Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol, 158, 486-94. https://doi.org/10.1093/aje/kwg171
- Nghi NQ, Lamontagne DS, Bingham A, et al (2010). Human papillomavirus vaccine introduction in Vietnam: formative research findings. Sex Health, 7, 262-70. https://doi.org/10.1071/SH09123
- PATH and National Institute of Hygiene and Epidemiology (NIHE) (2009). Shaping a strategy to introduce HPV vaccines in Vietnam: formative research results from the HPV vaccines: evidence for impact project. http://www.rho.org/files/rb3/Shaping_Strategy_Introduce_HPV_vaccines_Vietnam_PATH_2009.pdf.
- Paul P, LaMontagne DS, Le NT (2012). Knowledge of cervical cancer and HPV vaccine post-vaccination among mothers and daughters in Vietnam. Asian Pac J Cancer Prev, 13, 2587-92. https://doi.org/10.7314/APJCP.2012.13.6.2587
- Perkins RB, Anderson BL, Gorin SS, et al (2013). Challenges in cervical cancer prevention: a survey of U.S. obstetrician-gynecologists. Am J Prev Med, 45, 175-81. https://doi.org/10.1016/j.amepre.2013.03.019
- Poulos C, Yang JC, Levin C, et al (2011). Mothers' preferences and willingness to pay for HPV vaccines in Vinh Long Province, Vietnam. Soc Sci Med, 73, 226-34. https://doi.org/10.1016/j.socscimed.2011.05.029
- Romanowski B, de Borba PC, Naud PS, et al (2009). Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet, 374, 1975-85. https://doi.org/10.1016/S0140-6736(09)61567-1
- Rosenthal SL, Weiss TW, Zimet GD, et al (2011). Predictors of HPV vaccine uptake among women aged 19-26: importance of a physician's recommendation. Vaccine, 29, 890-5. https://doi.org/10.1016/j.vaccine.2009.12.063
- Stockwell MS, Rosenthal SL, Sturm LA, et al (2011). The effects of vaccine characteristics on adult women's attitudes about vaccination: a conjoint analysis study. Vaccine, 29, 4507-11. https://doi.org/10.1016/j.vaccine.2011.04.031
- Tsunematsu M, Kawasaki H, Masuoka Y, et al (2013). Factors affecting breast cancer screening behavior in Japan-assessment using the health belief model and conjoint analysis. Asian Pac J Cancer Prev, 14, 6041-8. https://doi.org/10.7314/APJCP.2013.14.10.6041
- Vadaparampil ST, Kahn JA, Salmon D, et al (2011). Missed clinical opportunities: provider recommendations for HPV vaccination for 11-12 year old girls are limited. Vaccine, 29, 8634-41. https://doi.org/10.1016/j.vaccine.2011.09.006
- Villa LL, Costa RL, Petta CA, et al (2005). Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol, 6, 271-8. https://doi.org/10.1016/S1470-2045(05)70101-7
- Vu LT, Bui D, Le HT (2013). Prevalence of cervical infection with HPV type 16 and 18 in Vietnam: implications for vaccine campaign. BMC Cancer, 13, 53. https://doi.org/10.1186/1471-2407-13-53
- Vu LT, Le HT (2011). Cervical human papilloma virus infection among the general female population in Vietnam: a situation analysis. Asian Pac J Cancer Prev, 12, 561-6.
- Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
- World Health Organization (WHO) (2014). Evidence based recommendations on human papilloma virus (HPV) vaccines schedules. Background paper for SAGE discussions, March 11, 2014. http://www.who.int/immunization/sage/meetings/2014/april/1_HPV_Evidence_based_recommendationsWHO_with_Appendices2_3.pdf
- Ylitalo KR, Lee H, Mehta NK (2013). Health care provider recommendation, human papillomavirus vaccination, and race/ethnicity in the US national immunization survey. Am J Public Health, 103, 164-9. https://doi.org/10.2105/AJPH.2011.300600
- Acceptability of two- versus three-dose human papillomavirus vaccination schedule among providers and mothers of adolescent girls: a mixed-methods study in five countries pp.1573-7225, 2018, https://doi.org/10.1007/s10552-018-1085-1
- Prevalence of human papillomavirus by geographical regions, sexual orientation and HIV status in China: a systematic review and meta-analysis vol.94, pp.6, 2018, https://doi.org/10.1136/sextrans-2017-053412